

**TOXICOLOGICAL PROFILE FOR  
TETRACHLOROETHYLENE**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Public Health Service  
Agency for Toxic Substances and Disease Registry**

**September 1997**

**DISCLAIMER**

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

**UPDATE STATEMENT**

A Toxicological Profile for tetrachloroethylene was released in April 1993. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry  
Division of Toxicology/Toxicology Information Branch  
1600 Clifton Road NE, E-29  
Atlanta, Georgia 30333



## FOREWORD

This toxicological profile is prepared in accordance with guidelines\* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



David Satcher, M.D., Ph.D.  
Administrator  
Agency for Toxic Substances and  
Disease Registry

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the Federal Register on April 29, 1996 (61 FR 18744). For prior versions of the list of substances, see Federal Register notices dated April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); and February 28, 1994 (59 FR 9486). Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.

**CONTRIBUTORS****CHEMICAL MANAGER(S)/AUTHOR(S):**

Yee-Wan Stevens, MS.  
ATSDR, Division of Toxicology, Atlanta, GA

Carol Eisenmann, Ph.D.  
Sciences International, Inc., Alexandria, VA

**THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:**

1. Green Border Review. Green Border review assures consistency with ATSDR policy.
2. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
3. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.



**PEER REVIEW**

A peer review panel was assembled for tetrachloroethylene. The panel consisted of the following members:

1. Dr. Lee R. Shull, Toxicologist, Poster Wheeler Environmental, Sacramento, California
2. Mr. Lyman K. Skory, Private Consultant, Midland, Michigan
3. Richard D. Stewart, M.D., M.P.H., Adjunct Professor, Department of Pharmacology and Toxicology, The Medical College of Wisconsin, Milwaukee, Wisconsin

These experts collectively have knowledge of tetrachloroethylene's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.



## CONTENTS

FOREWORD .....	v
CONTRIBUTORS .....	vii
PEER REVIEW .....	ix
LIST OF FIGURES .....	xv
LIST OF TABLES .....	xvii
1. PUBLIC HEALTH STATEMENT .....	1
1.1 WHAT IS TETRACHLOROETHYLENE? .....	1
1.2 WHAT HAPPENS TO TETRACHLOROETHYLENE WHEN IT ENTERS THE ENVIRONMENT? .....	2
1.3 HOW MIGHT I BE EXPOSED TO TETRACHLOROETHYLENE? .....	2
1.4 HOW CAN TETRACHLOROETHYLENE ENTER AND LEAVE MY BODY? .....	4
1.5 HOW CAN TETRACHLOROETHYLENE AFFECT MY HEALTH? .....	5
1.6 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO TETRACHLOROETHYLENE? .....	6
1.7 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH? .....	7
1.8 WHERE CAN I GET MORE INFORMATION? .....	8
2. HEALTH EFFECTS .....	11
2.1 INTRODUCTION .....	11
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE .....	11
2.2.1 Inhalation Exposure .....	13
2.2.1.1 Death .....	13
2.2.1.2 Systemic Effects .....	14
2.2.1.3 Immunological and Lymphoreticular Effects .....	43
2.2.1.4 Neurological Effects .....	43
2.2.1.5 Reproductive Effects .....	51
2.2.1.6 Developmental Effects .....	53
2.2.1.7 Genotoxic Effects .....	54
2.2.1.8 Cancer .....	55
2.2.2 Oral Exposure .....	60
2.2.2.1 Death .....	60
2.2.2.2 Systemic Effects .....	61
2.2.2.3 Immunological and Lymphoreticular Effects .....	79
2.2.2.4 Neurological Effects .....	80
2.2.2.5 Reproductive Effects .....	81
2.2.2.6 Developmental Effects .....	82
2.2.2.7 Genotoxic Effects .....	83
2.2.2.8 Cancer .....	83

2.2.3	Dermal Exposure	85
2.2.3.1	Death	85
2.2.3.2	Systemic Effects	86
2.2.3.3	Immunological and Lymphoreticular Effects	87
2.2.3.4	Neurological Effects	87
2.2.3.5	Reproductive Effects	88
2.2.3.6	Developmental Effects	88
2.2.3.7	Genotoxic Effects	88
2.2.3.8	Cancer	88
2.3	TOXICOKINETICS	88
2.3.1	Absorption	89
2.3.1.1	Inhalation Exposure	89
2.3.1.2	Oral Exposure	91
2.3.1.3	Dermal Exposure	91
2.3.2	Distribution	93
2.3.2.1	Inhalation Exposure	96
2.3.2.2	Oral Exposure	98
2.3.2.3	Dermal Exposure	98
2.3.3	Metabolism	98
2.3.4	Elimination and Excretion	104
2.3.4.1	Inhalation Exposure	104
2.3.4.2	Oral Exposure	106
2.3.4.3	Dermal Exposure	107
2.3.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	108
2.4	MECHANISMS OF ACTION	114
2.4.1	Pharmacokinetic Mechanisms	114
2.4.2	Mechanisms of Toxicity	114
2.4.3	Animal-to-Human Extrapolations	117
2.5	RELEVANCE TO PUBLIC HEALTH	117
2.6	BIOMARKERS OF EXPOSURE AND EFFECT	142
2.6.1	Biomarkers Used to Identify or Quantify Exposure to Tetrachloroethylene	143
2.6.2	Biomarkers Used to Characterize Effects Caused by Tetrachloroethylene	145
2.7	INTERACTIONS WITH OTHER CHEMICALS	146
2.8	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	148
2.9	METHODS FOR REDUCING TOXIC EFFECTS	149
2.9.1	Reducing Peak Absorption Following Exposure	150
2.9.2	Reducing Body Burden	150
2.9.3	Interfering with the Mechanism of Action for Toxic Effects	151
2.10	ADEQUACY OF THE DATABASE	152
2.10.1	Existing Information on Health Effects of Tetrachloroethylene	152
2.10.2	Identification of Data Needs	154
2.10.3	On-going Studies	168
3.	CHEMICAL AND PHYSICAL INFORMATION	169
3.1	CHEMICAL IDENTITY	169
3.2	PHYSICAL AND CHEMICAL PROPERTIES	169

4. PRODUCTION, IMPORT, USE, AND DISPOSAL	173
4.1 PRODUCTION	173
4.2 IMPORT/EXPORT	174
4.3 USE	177
4.4 DISPOSAL	178
5. POTENTIAL FOR HUMAN EXPOSURE	179
5.1 OVERVIEW	179
5.2 RELEASES TO THE ENVIRONMENT	179
5.2.1 Air	179
5.2.2 Water	181
5.2.3 Soil	184
5.3 ENVIRONMENTAL FATE	185
5.3.1 Transport and Partitioning	185
5.3.2 Transformation and Degradation	188
5.3.2.1 Air	188
5.3.2.2 Water	189
5.3.2.3 Sediment and Soil	191
5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	191
5.4.1 Air	191
5.4.2 Water	194
5.4.3 Sediment and Soil	195
5.4.4 Other Environmental Media	196
5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	197
5.6 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	202
5.7 ADEQUACY OF THE DATABASE	204
5.7.1 Identification of Data Needs	204
5.7.2 On-going Studies	207
6. ANALYTICAL METHODS	209
6.1 BIOLOGICAL MATERIALS	209
6.2 ENVIRONMENTAL SAMPLES	214
6.3 ADEQUACY OF THE DATABASE	220
6.3.1 Identification of Data Needs	221
6.3.2 On-going Studies	222
7. REGULATIONS AND ADVISORIES	225
8. REFERENCES	233
9. GLOSSARY	275
APPENDICES	
A. MINIMAL RISK LEVEL WORKSHEETS	A-1
B. USER'S GUIDE	B-1
C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS	C-1



## LIST OF FIGURES

2-1	Levels of Significant Exposure to Tetrachloroethylene - Inhalation . . . . .	30
2-2	Levels of Significant Exposure to Tetrachloroethylene - Oral . . . . .	71
2-3	Metabolism of Tetrachloroethylene by Humans . . . . .	99
2-4	Proposed Pathways for the Metabolism of Tetrachloroethylene to Metabolites in Addition to Trichloroacetic Acid . . . . .	102
2-5	Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical . . . . .	110
2-6	Existing Information on Health Effects of Tetrachloroethylene . . . . .	153
5-1	Frequency of NPL Sites with Tetrachloroethylene Contamination . . . . .	180



## LIST OF TABLES

2-1	Levels of Significant Exposure to Tetrachloroethylene - Inhalation . . . . .	15
2-2	Hepatocellular Neoplasms in B6C3F <sub>1</sub> Mice Exposed to Tetrachloroethylene for 103 Weeks by Inhalation . . . . .	59
2-3	Levels of Significant Exposure to Tetrachloroethylene - Oral . . . . .	62
2-4	Partition Coefficients for Tetrachloroethylene in Mice, Rats, Dogs, and Humans . . . . .	94
2-5	Metabolism of Tetrachloroethylene in Mice, Rats, and Humans . . . . .	103
2-6	Range of Physiological Parameters Used in PBPK Modeling for Tetrachloroethylene . . . . .	112
2-7	Genotoxicity of Tetrachloroethylene <i>In Vitro</i> . . . . .	135
2-8	Genotoxicity of Tetrachloroethylene <i>In Vivo</i> . . . . .	136
3-1	Chemical Identity of Tetrachloroethylene . . . . .	170
3-2	Physical and Chemical Properties of Tetrachloroethylene . . . . .	171
4-1	Facilities That Manufacture or Process Tetrachloroethylene . . . . .	175
5-1	Releases to the Environment from Facilities That Manufacture or Process Tetrachloroethylene . . . . .	182
6-1	Analytical Methods for Determining Tetrachloroethylene in Biological Samples . . . . .	211
6-2	Analytical Methods for Determining Tetrachloroethylene in Environmental Samples . . . . .	215
7-1	Regulations and Guidelines Applicable to Tetrachloroethylene . . . . .	226